Introduction: This short case series presents the results from 5 patients with bilateral chronic
had bilateral, chronic DME and had received prior laser and anti-VEGF therapy. Visual and anatomic outcomes were investigated 12 months post-FAc implant in both eyes. Results: At baseline, central retinal thickness (CRT) was 645.3 ± 176.1 microns (mean ± standard deviation), intraocular pressure (IOP) was 13.7 ± 3.6 mmHg and visual acuity (VA) was 44.5 ± 18.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters.
Mean CRT improved at 6 months (341.7 ± 169.7 microns) and 12 months (287.4 ± 103.1 microns) and there were concurrent improvements in VA (ETDRS letters were 56 ± 16 and 55 ± 16 at 6 and 12 months, respectively). Mean IOP was stable throughout and B21 mmHg. Left and right eyes were compared in the 5 patients by plotting changes in CFT, IOP and VA at 12 months, from baseline levels. Conclusion: This bilateral case series demonstrates the effectiveness of a sustained, controlled low dose of FAc in the management of bilateral DME over a 12-month period. The
FAc implant has shown to work well in treatment of bilateral DME, although longer follow-up of these patients is still needed.
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CASE SERIES
In everyday clinical practice, patients frequently present with bilateral diabetic macular edema (DME), yet there is a paucity of reported data on the bilateral use of DME therapies [1] . ILUVIEN Ò [fluocinolone acetonide (FAc) implant] is indicated for the treatment of vision impairment associated with chronic DME, considered insufficiently responsive to available therapies [2] . A single implant in the affected eye is recommended, with the fellow eye being available for therapy but not at the same time or visit as the first eye [2] . This inevitably means that treatment of the fellow eye is delayed; however, early intervention is important in the management of DME as prolonged edema can lead to irreversible damage and permanent vision loss [3] .
The structural and functional responses following bilateral intravitreal injections of the FAc implant have been reported previously [4] . The objective of this case series is to report the structural and functional Table 2 shows the mean changes from baseline. There was a decrease in Table 2 shows the mean changes from baseline. At 6 and 12 months, VA was sustained or improved in 9 out of 10 patients with letter gains from baseline ranging between 0 and 35 ETDRS letters. Overall, mean VA increased by 11.0 ± 13.1 and 10.5 ± 13.0 ETDRS letters after 6 and 12 months, respectively, from a baseline of 44.5 ± 18.6 ETDRS letters.
Intraocular pressure (IOP) was also measured at baseline (mean of 13.7 ± 3.6 mmHg), 6 months (mean 15.5 ± 4.0 mmHg) and 12 months (mean 16.0 ± 3.3 mmHg). Table 2 shows the mean changes from baseline. In all cases, IOP remained B21 mmHg.
CONCLUSION
The patients followed up in our bilateral case 
